Pieris Pharmaceuticals (PIRS)
(Delayed Data from NSDQ)
$10.15 USD
+0.36 (3.70%)
Updated May 31, 2024 04:00 PM ET
After-Market: $10.40 +0.25 (2.46%) 6:40 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Pieris Pharmaceuticals, Inc. [PIRS]
Reports for Purchase
Showing records 81 - 91 ( 91 total )
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage of Pieris Pharmaceuticals with a Buy rating and 12- month target price of $7/share
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J